Patents by Inventor Joseph H. Phillips

Joseph H. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating cancer with a combination of a PD-1 antagonist and dinaciclib
    Patent number: 9827309
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: November 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Richard Strack, Robert Booher, Venkataraman Sriram, Joseph H. Phillips
  • TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR
    Publication number: 20160303231
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: December 3, 2014
    Publication date: October 20, 2016
    Inventors: Robert Iannone, Rodolfo F. Perini, Joseph H. Phillips, Sriram Venkataraman, Elaine Marie Paul
  • TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND DINACICLIB
    Publication number: 20160193334
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: August 15, 2014
    Publication date: July 7, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Peter Richard Strack, Robert Booher, Venkataraman Sriram, Joseph H. Phillips
  • MDL-1 ligand
    Patent number: 9284377
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Joseph H. Phillips
  • FDF03 ANTIBODIES AND USES THEREOF
    Publication number: 20160068597
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • MDL-1 LIGAND
    Publication number: 20150368344
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Application
    Filed: June 19, 2015
    Publication date: December 24, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Maribel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Phillips
  • FDF03 ANTIBODIES AND USES THEREOF
    Publication number: 20150104453
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 16, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141444
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141445
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • FDF03 ANTIBODIES AND USES THEREOF
    Publication number: 20130156771
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Application
    Filed: February 14, 2013
    Publication date: June 20, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
    Publication number: 20130034561
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: October 12, 2012
    Publication date: February 7, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • FDF03 ANTIBODIES AND USES THEREOF
    Publication number: 20120258110
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Applicant: Schering Corporation
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • Ox2 Receptor Homologs
    Publication number: 20120231003
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 13, 2012
    Applicants: Medical Research Council, Schering Corporation
    Inventors: A. Neil Barclay, Marion H. Brown, Daniel M. Gorman, Lewis L. Lanier, Gavin J. Wright, Holly Cherwinski, Joseph H. Phillips, Robert M. Hoek, Jonathan D. Sedgwick
  • Methods of modulating CD200 receptors
    Patent number: 8263070
    Abstract: Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: September 11, 2012
    Assignee: Schering Corporation
    Inventors: Holly M. Cherwinski, Michael E. Bigler, Jonathon D. Sedgwick, Joseph H. Phillips
  • Use of bispecific antibodies to regulate immune responses
    Patent number: 8236309
    Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: August 7, 2012
    Assignee: Schering Corporation
    Inventors: Michael Eric Bigler, Holly Marie Cherwinski, Joseph H. Phillips
  • MDL-1 USES
    Publication number: 20120177647
    Abstract: The invention provides methods for treating bone resorption disorders with antagonists of MDL-1.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: Schering Corporation
    Inventors: Michael E. Bigler, Daniel J. Cua, Barbara Joyce-Shaikh, Joseph H. Phillips
  • Antibodies to CD200R
    Patent number: 8212008
    Abstract: The present invention relates to binding compounds specific for the human inhibitory CD200R and uses thereof. More specifically, the invention relates to antibodies that recognize the human inhibitory CD200R and modulates its activity in inflammatory and autoimmune disorders.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: July 3, 2012
    Assignee: Schering Corporation
    Inventors: Leonard G. Presta, Holly M. Cherwinski, Joseph H. Phillips
  • Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies
    Patent number: 8178094
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • Anti-MDL-1 antibodies
    Patent number: 8153134
    Abstract: Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: April 10, 2012
    Assignee: Schering Corporation
    Inventors: Michael E. Bigler, Paul G. Heyworth, Joseph H. Phillips, Leonard G. Presta
  • ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
    Publication number: 20120020990
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 26, 2012
    Applicant: Schering Corporation
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips, JR.